Patents by Inventor Laura M. Hales
Laura M. Hales has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12076366Abstract: The invention provides non-hormonal vitamin D conjugated to apelin proteins that result in increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. In some embodiments, the vitamin D targeting groups are coupled to the apelin proteins via the third carbon on the vitamin D backbone.Type: GrantFiled: July 3, 2020Date of Patent: September 3, 2024Assignee: Extend Biosciences, Inc.Inventors: Tarik Soliman, Laura M. Hales, Daniel B. Hall, Christopher So, Howard P. Sard, Vishnumurthy Hegde
-
Patent number: 11116816Abstract: The invention provides a parathyroid hormone (PTH) compound comprising a PTH peptide. The PTH compound has a significantly increased bioavailability or circulating half-life when compared to a bioavailability or a circulating half-life of a native form of the PTH peptide. The PTH compound has a significantly greater serum concentration at multiple timepoints post-administration to a rat when compared to that of a native PTH peptide.Type: GrantFiled: January 29, 2019Date of Patent: September 14, 2021Assignee: Extend Biosciences, Inc.Inventors: Tarik Soliman, Laura M. Hales, Daniel B. Hall, Christopher So, Howard P. Sard, Vishnumurthy Hegde
-
Publication number: 20210008153Abstract: The invention provides non-hormonal vitamin D conjugated to apelin proteins that result in increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. In some embodiments, the vitamin D targeting groups are coupled to the apelin proteins via the third carbon on the vitamin D backbone.Type: ApplicationFiled: July 3, 2020Publication date: January 14, 2021Applicant: Extend Biosciences, Inc.Inventors: Tarik Soliman, Laura M. Hales, Daniel B. Hall, Christopher So, Howard P. Sard, Vishnumurthy Hegde
-
Patent number: 10702574Abstract: The invention provides non-hormonal vitamin D conjugated to apelin proteins that result in increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. In some embodiments, the vitamin D targeting groups are coupled to the apelin proteins via the third carbon on the vitamin D backbone.Type: GrantFiled: February 11, 2017Date of Patent: July 7, 2020Assignee: Extend Biosciences, Inc.Inventors: Tarik Soliman, Laura M. Hales, Daniel B. Hall, Christopher So, Howard P. Sard, Vishnumurthy Hegde
-
Patent number: 10420819Abstract: The invention provides non-hormonal vitamin D conjugated to insulin peptides that result in the peptides having increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. The vitamin D targeting groups are coupled to the insulin peptides via the third carbon on the vitamin D backbone.Type: GrantFiled: March 23, 2017Date of Patent: September 24, 2019Assignee: Extend Biosciences, Inc.Inventors: Tarik Soliman, Laura M. Hales, Daniel B. Hall, Howard Sard, Vishnumurthy Hegde
-
Patent number: 10406202Abstract: The invention provides non-hormonal vitamin D conjugated via the third carbon on the vitamin D backbone to parathyroid hormone (PTH) proteins that result in increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms.Type: GrantFiled: July 12, 2018Date of Patent: September 10, 2019Assignee: Extend Biosciences, Inc.Inventors: Tarik Soliman, Laura M. Hales, Daniel B. Hall, Christopher So, Howard P. Sard, Vishnumurthy Hegde
-
Publication number: 20190183966Abstract: The invention provides a parathyroid hormone (PTH) compound comprising a PTH peptide. The PTH compound has a significantly increased bioavailability or circulating half-life when compared to a bioavailability or a circulating half-life of a native form of the PTH peptide. The PTH compound has a significantly greater serum concentration at multiple timepoints post-administration to a rat when compared to that of a native PTH peptide.Type: ApplicationFiled: January 29, 2019Publication date: June 20, 2019Applicant: Extend Biosciences, Inc.Inventors: Tarik Soliman, Laura M. Hales, Daniel B. Hall, Christopher So, Howard P. Sard, Vishnumurthy Hegde
-
Publication number: 20180311307Abstract: The invention provides non-hormonal vitamin D conjugated via the third carbon on the vitamin D backbone to parathyroid hormone (PTH) proteins that result in increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms.Type: ApplicationFiled: July 12, 2018Publication date: November 1, 2018Applicant: Extend Biosciences, Inc.Inventors: Tarik Soliman, Laura M. Hales, Daniel B. Hall, Christopher So, Howard P. Sard, Vishnumurthy Hegde
-
Patent number: 9884124Abstract: The invention provides carriers that enhance the absorption, half-life or bioavailability of therapeutic compounds. The carriers comprise targeting groups that bind the Vitamin D Binding protein (DBP), conjugation groups for coupling the targeting groups to the therapeutic compounds, and optionally scaffolding moieties.Type: GrantFiled: February 6, 2016Date of Patent: February 6, 2018Assignee: Extend Biosciences, Inc.Inventors: Tarik Soliman, Laura M. Hales, Howard P. Sard, Mukkanti Amere
-
Patent number: 9789197Abstract: The invention provides non-hormonal vitamin D conjugated to therapeutic RNA compounds that result in the compounds having increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. The vitamin D targeting groups are coupled to the therapeutic RNA compounds via the third carbon on the vitamin D backbone.Type: GrantFiled: October 21, 2015Date of Patent: October 17, 2017Assignee: Extend Biosciences, Inc.Inventors: Tarik Soliman, Laura M. Hales, Daniel B. Hall, Howard P. Sard, Vishnumurthy Hegde
-
Publication number: 20170252410Abstract: The invention provides non-hormonal vitamin D conjugated to insulin peptides that result in the peptides having increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. The vitamin D targeting groups are coupled to the insulin peptides via the third carbon on the vitamin D backbone.Type: ApplicationFiled: March 23, 2017Publication date: September 7, 2017Applicant: Extend Biosciences, Inc.Inventors: Tarik Soliman, Laura M. Hales, Daniel B. Hall, Howard Sard, Vishnumurthy Hegde
-
Publication number: 20170216449Abstract: The invention provides non-hormonal vitamin D conjugated to apelin proteins that result in increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. In some embodiments, the vitamin D targeting groups are coupled to the apelin proteins via the third carbon on the vitamin D backbone.Type: ApplicationFiled: February 11, 2017Publication date: August 3, 2017Applicant: Extend Biosciences, Inc.Inventors: Tarik Soliman, Laura M. Hales, Daniel B. Hall, Christopher So, Howard P. Sard, Vishnumurthy Hegde
-
Patent number: 9616109Abstract: The invention provides non-hormonal vitamin D conjugated to insulin peptides that result in the peptides having increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. The vitamin D targeting groups are coupled to the insulin peptides via the third carbon on the vitamin D backbone.Type: GrantFiled: October 21, 2015Date of Patent: April 11, 2017Assignee: Extend Biosciences, Inc.Inventors: Tarik Soliman, Laura M. Hales, Daniel B. Hall, Howard Sard, Vishnumurthy Hegde
-
Patent number: 9585934Abstract: The invention provides non-hormonal vitamin D conjugated to apelin proteins that result in increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. In some embodiments, the vitamin D targeting groups are coupled to the apelin proteins via the third carbon on the vitamin D backbone.Type: GrantFiled: October 21, 2015Date of Patent: March 7, 2017Assignee: Extend Biosciences, Inc.Inventors: Tarik Soliman, Laura M. Hales, Daniel B. Hall, Christopher So, Howard P. Sard, Vishnumurthy Hegde
-
Publication number: 20160144049Abstract: The invention provides carriers that enhance the absorption, half-life or bioavailability of therapeutic compounds. The carriers comprise targeting groups that bind the Vitamin D Binding protein (DBP), conjugation groups for coupling the targeting groups to the therapeutic compounds, and optionally scaffolding moieties.Type: ApplicationFiled: February 6, 2016Publication date: May 26, 2016Applicant: Extend Biosciences, Inc.Inventors: Tarik Soliman, Laura M. Hales, Howard P. Sard, Mukkanti Amere
-
Publication number: 20160114049Abstract: The invention provides non-hormonal vitamin D conjugated to therapeutic RNA compounds that result in the compounds having increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. The vitamin D targeting groups are coupled to the therapeutic RNA compounds via the third carbon on the vitamin D backbone.Type: ApplicationFiled: October 21, 2015Publication date: April 28, 2016Applicant: EXTEND BIOSCIENCES, INC.Inventors: Tarik Soliman, Laura M. Hales, Daniel B. Hall, Howard P. Sard, Vishnumurthy Hegde
-
Publication number: 20160113993Abstract: The invention provides non-hormonal vitamin D conjugated to apelin proteins that result in increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. In some embodiments, the vitamin D targeting groups are coupled to the apelin proteins via the third carbon on the vitamin D backbone.Type: ApplicationFiled: October 21, 2015Publication date: April 28, 2016Applicant: EXTEND BIOSCIENCES, INC.Inventors: Tarik Soliman, Laura M. Hales, Daniel B. Hall, Christopher So, Howard P. Sard, Vishnumurthy Hegde
-
Publication number: 20160114001Abstract: The invention provides non-hormonal vitamin D conjugated to insulin peptides that result in the peptides having increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. The vitamin D targeting groups are coupled to the insulin peptides via the third carbon on the vitamin D backbone.Type: ApplicationFiled: October 21, 2015Publication date: April 28, 2016Applicant: EXTEND BIOSCIENCES, INC.Inventors: Tarik Soliman, Laura M. Hales, Daniel B. Hall, Howard Sard, Vishnumurthy Hegde
-
Patent number: 9289507Abstract: The invention provides carriers that enhance the absorption, half-life or bioavailability of therapeutic compounds. The carriers comprise targeting groups that bind the Vitamin D Binding protein (DBP), conjugation groups for coupling the targeting groups to the therapeutic compounds, and optionally scaffolding moieties.Type: GrantFiled: March 14, 2013Date of Patent: March 22, 2016Assignee: Extend Biosciences, Inc.Inventors: Tarik Soliman, Laura M. Hales, Howard P. Sard, Mukkanti Amere
-
Patent number: 9173950Abstract: The invention provides carriers that enhance the absorption, half-life or bioavailability of Ghrelin peptides. The carriers comprise targeting groups that bind the Vitamin D Binding protein (DBP), conjugation groups for coupling the targeting groups to the therapeutic compounds, and optionally scaffolding moieties.Type: GrantFiled: November 15, 2014Date of Patent: November 3, 2015Assignee: Extend Biosciences, Inc.Inventors: Tarik Soliman, Laura M. Hales, Howard P. Sard, Mukkanti Amere